Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.

Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis

Inclusion Criteria:

• Male or Female ages 18 years and older.
• Mild RA.
• Body weight less than 100 kg.

Exclusion Criteria:

• Wheelchair-bound or bedridden.
• Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit.
• Intra-articular, intramuscular or intravenous (IV) administration of corticosteroids within 28 days prior to the Screening visit.
• Prior treatment with any TNF antagonist, including adalimumab.
• Positive tuberculin PPD 5.
• Female subjects who are pregnant or breast-feeding.
• History of HIV or of being immuno-compromised.
• History of malignancy.
• Poorly controlled medical condition.